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Introduction
Controlled release systems for low-molecular-weight 
drugs and proteins have become a multibillion dollar in-
dustry, with products such as Nutropin Depot, Gliadel 
wafer, Norplant, and CYPHER Stent. These systems il-
lustrate the potential advantages of controlled release, 
which include: (i) drug levels maintained within a desir-
able range, (ii) localized delivery to a target tissue or cell 
type to avoid adverse side effects, (iii) decreased dose or 
number of dosages, and (iv) facilitated delivery for frag-
ile compounds (i.e., short half-lives). The adaptation of 
controlled release technologies to the delivery of nonvi-
ral and viral vectors has the potential to overcome extra-
cellular barriers that limit gene therapy. Controlled re-
lease can maintain elevated DNA concentrations in the 
cellular microenvironment, which improves gene de-
livery.1 Localized vector delivery to specific tissues can 
avoid distribution to distant tissues, leading to ectopic 
gene expression, toxicity to nontarget cells, and a strong 
immune response. Additionally, viral and nonviral vec-
tors may have a relatively short half-life,2–4 and delivery 
vehicles can prevent their degradation and/or provide 
a sustained release. This review examines the mecha-
nisms of gene delivery from biomaterials and discusses 
how continuing advances will increase the applicability 
of controlled release to gene delivery.
Delivery Mechanisms
Controlled release systems typically employ polymeric 
biomaterials that deliver vectors according to two gen-
eral mechanisms: (i) polymeric release, in which the 
DNA is released from the polymer, or (ii) substrate-me-
diated delivery, in which DNA is retained at the surface. 
For polymeric release, DNA is entrapped within the ma-
terial and released into the environment, with release 
typically occurring through a combination of diffusion 
and polymer degradation. Polymeric delivery may en-
hance gene transfer by first protecting DNA from deg-
radation and then maintaining the vector at effective 
concentrations, extending the opportunity for internal-
ization. DNA release into the tissue can occur rapidly, as 
in bolus delivery, or extend over days to months.5–7 For 
rapid release, levels would be expected to rise quickly 
and decline as the DNA is cleared or degraded. For sus-
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Adapting controlled release technologies to the delivery of DNA has the potential to overcome extracellular barriers that limit 
gene therapy. Controlled release systems can enhance gene delivery and increase the extent and duration of transgene expres-
sion relative to more traditional delivery methods (e.g., injection). These systems typically deliver vectors locally, which can avoid 
distribution to distant tissues, decrease toxicity to nontarget cells, and reduce the immune response to the vector. Delivery vehi-
cles for controlled release are fabricated from natural and synthetic polymers, which function either by releasing the vector into 
the local tissue environment or by maintaining the vector at the polymer surface. Vector release or binding is regulated by the ef-
fective affinity of the vector for the polymer, which depends upon the strength of molecular interactions. These interactions oc-
cur through nonspecific binding based on vector and polymer composition or through the incorporation of complementary bind-
ing sites (e.g., biotin–avidin). This review examines the delivery of nonviral and viral vectors from natural and synthetic polymers 
and presents opportunities for continuing developments to increase their applicability.
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tained delivery, the concentration may be maintained 
within an appropriate range by adjusting the release to 
replace DNA that is cleared or degraded. Conversely, 
substrate-mediated delivery, also termed solid-phase 
delivery, describes the immobilization of DNA to a bio-
material or extracellular matrix, which functions to sup-
port cell adhesion as well as migration and places DNA 
directly in the cellular microenvironment. The immobi-
lization of DNA to the matrix may seem counterintui-
tive given the need for cellular internalization to achieve 
expression; however, natural and synthetic corollaries 
exist for growth factors and viral vectors. Growth fac-
tors associate with the extracellular matrix, function-
ing directly from the matrix or upon release.8 Addition-
ally, many viral vectors associate with the extracellular 
matrix as a means to facilitate cellular binding and in-
ternalization.9, 10 In substrate-mediated delivery, DNA 
is concentrated at the delivery site and targeted to the 
cells that are adhered to the substrate.11, 12 Cells cultured 
on the substrate can internalize the DNA either directly 
from the surface or by degrading the linkage between 
the vector and the material.
Molecular interactions between the vector and the 
polymer dictate whether the DNA is released from or 
bound to the delivery vehicle. Viral and nonviral vec-
tors, which contain negatively charged DNA or RNA 
potentially complexed with proteins, cationic polymers, 
or cationic lipids, interact with polymeric biomaterials 
through nonspecific mechanisms, including hydropho-
bic, electrostatic, and van der Waals interactions. These 
interactions have been well characterized for adsorp-
tion and release of proteins from polymeric systems,13, 14 
Nonspecific binding depends upon the molecular com-
position of the vector (e.g., lipid, polymer, protein) and 
the relative quantity of each (e.g., N/P). Alternatively, 
specific interactions can be introduced through com-
plementary functional groups on the vector and poly-
mer, such as antigen–antibody or biotin–avidin, to con-
trol vector binding to the substrate. The effective affinity 
of vector for polymer is determined by the strength of 
these molecular interactions, which may also be influ-
enced by environmental conditions (e.g., ionic strength, 
pH), binding-induced conformational changes, or vec-
tor unpacking. Delivery from most polymeric systems 
likely occurs through a combination of binding and re-
lease mechanisms, and both the vector and the polymer 
can be designed to regulate these interactions.
Vehicle Formulations
Vehicles for gene delivery can be fabricated from both 
natural and synthetic polymers and processed into a 
variety of forms, including nanospheres, microspheres, 
or scaffolds. Nanospheres are particles with diameters 
ranging from approximately 50 to 700 nm,15 consistent 
with the size of viral and nonviral vectors. Nanoparti-
cles are internalized and release DNA intracellularly. 
In contrast, microspheres, with diameters ranging from 
2 to 100 μm, are not readily internalized, but retained 
within the tissue to release DNA.16, 17 Released DNA 
can transfect cells at the delivery site, with the protein 
product acting locally or distributed systemically.17, 18 
Alternatively, polymeric scaffolds function to define a 
three-dimensional space and can either be implanted 
or be designed to solidify upon injection. These scaf-
folds can deliver DNA to cells within the surrounding 
tissue or can target those cells infiltrating the scaffold.7, 
18 The scaffold can also distribute the vector through-
out a three-dimensional space, and transfection on a 
three-dimensional construct may extend transgene 
expression.19
A variety of natural and synthetic materials have 
been employed for DNA delivery, which can be cate-
gorized as either hydrophobic [e.g., poly(lactide-co-gly-
colide) (PLG), polyanhydrides] or hydrophilic polymers 
[e.g., hyaluronic acid (HA), collagen, poly(ethylene gly-
col) (PEG)]. Synthetic polymers such as PLG and poly-
anhydrides have been widely used in drug delivery ap-
plications, as they are biocompatible and available in 
a range of copolymer ratios to control their degrada-
tion.20 Drug release from these polymers typically oc-
curs through a combination of surface desorption, drug 
diffusion, and polymer degradation.21 For DNA deliv-
ery, polymer processing techniques are being devel-
oped to fabricate a range of geometries and properties 
while retaining the activity of the vector during process-
ing and release.22, 23 Alternatively, mild processing con-
ditions can be employed to process hydrophilic poly-
mers into hydrogels. These hydrogels are often more 
than 98% water and maintain the activity of encapsu-
lated vectors, which are released by diffusion from the 
polymer network.6 Crosslinking the polymer or increas-
ing the density can slow the release and allow network 
degradation to control the rate.24–26 These hydrophilic 
polymers, along with some hydrophobic polymers, con-
tain functional groups (e.g., carboxylic acids, amines) in 
the polymer backbone that can be readily modified, al-
lowing interactions between the polymer and the vector 
to be manipulated.
Plasmid delivery
Plasmid DNA delivery by physical methods generally 
results in low but sustained expression in vivo, which 
is limited by poor uptake due to factors such as degra-
dation and clearance.27, 28 Physical (e.g., ultrasound, hy-
drodynamic injection) methods are continually being 
improved to enhance cellular uptake of DNA by alter-
ing cell permeability.27, 29 Plasmid uptake may involve 
intrinsic cellular processes, but the processes governing 
intracellular transport remain elusive. Following deliv-
ery to the nucleus, expression can typically occur over 
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time scales of days to weeks or months.29 Extracellular 
factors that limit delivery include plasmid clearance or 
degradation, which can be mediated by sequence-spe-
cific recognition from the immune system. Immune re-
sponses to the plasmid are affected by the methylation 
pattern of CpG sequences that can affect the duration of 
transgene expression.29 Polymeric delivery represents 
an alternative approach that can increase residence time 
within the tissue and protect against degradation. Plas-
mids (103–104 bp) have effective hydrodynamic diame-
ters in excess of 100 nm and a highly negative surface 
charge density.30 The large size of the DNA limits trans-
port through tissues, resulting in diffusion coefficients 
on the order of 10-9 to 10-12 cm2/s,31 and promotes local-
ized delivery when polymers are inserted into a tissue.10 
In the following paragraphs, we limit our discussion of 
polymeric delivery systems primarily to plasmid deliv-
ery, though these systems may also benefit oligonucle-
otide or siRNA delivery.32
Plasmid DNA interacts weakly with many polymers, 
leading to in vitro release from the vehicle with rates 
modulated by the polymer properties. Many synthetic 
and natural polymers are negatively charged, and thus 
the weak interactions likely result from repulsive charge 
interactions between plasmid and polymer. Collagen-
based materials release plasmid DNA for times ranging 
from hours to days.6, 24 HA-based hydrogels also release 
the DNA; however, the rate of release can be controlled 
by the extent of crosslinking.26, 33 Sustained release and 
delayed release was achieved with hydrogels composed 
of PEG with lactic acid segments, based on the number 
of degradable lactic acid units.25 For hydrogels formed 
by crosslinking, the approach must be adjusted to avoid 
damaging the integrity of the DNA.25 For synthetic poly-
mers such as PLG, the integrity of the DNA can be af-
fected by degradation of the polymer to lactic acid and 
glycolic acid.7 PLG polymers can provide release rates 
ranging from a few days to more than 60 days, with the 
fabrication method and the polymer composition regu-
lating release.7, 23, 34, 35 Ethylene vinyl-co-acetate (EVAc) 
polymers can similarly provide a sustained release of 
DNA on the time scale of weeks.36, 37
DNA-releasing polymers administered to multiple 
sites in vivo have demonstrated the capacity to trans-
fect cells locally and promote sustained protein pro-
duction.18 Although successful gene transfer has been 
achieved, the design parameters that relate system prop-
erties to the quantity and duration of transgene expres-
sion are not well understood. For example, an injectable 
PLG formulation delivered subcutaneously led to 28 days 
of expression with 50 μg of DNA.34 An implantable PLG 
scaffold delivering 500 μg of DNA was able to transfect 
cells within and adjacent to the scaffold.7 EVAc disks im-
planted intravaginally induced gene expression for 28 
days with 45 μg of DNA.36 Collagen minipellets contain-
ing 50 μg of DNA administered intramuscularly elicited 
systemic effects for at least 60 days, which was signifi-
cantly longer than direct DNA injection.17 Similarly, col-
lagen implanted into a bone defect transfected cells lo-
cally with 1 mg of DNA. Controlled studies to correlate 
scaffold design with in vivo gene delivery are needed to 
optimize the development of delivery systems.
Nanospheres loaded with plasmid DNA represent 
an alternative to the traditional complexation agents. 
PLG nanoparticles are internalized by cells and a frac-
tion escape the endosome within 10 min of incubation, 
which is proposed to occur through charge reversal.38 
The DNA likely diffuses from the pores of the nanopar-
ticles, as opposed to decomplexing from a cationic poly-
mer or lipid. Transfection levels achieved in vitro with 
these nanoparticles are significantly lower than with a 
bolus delivery of lipoplexes.39, 40 However, a substan-
tial increase in expression was observed through 1 week 
of culture, suggesting that the nanospheres provided 
a controlled release intracellularly. Nanospheres fab-
ricated from natural polymers (gelatin, chitosan) pro-
vided transfection that was comparable to that obtained 
by Lipofectamine.41 Gelatin was crosslinked to stabilize 
the nanospheres and provided some protection against 
nuclease degradation.42 Intramuscular delivery of these 
nanospheres produced higher and more sustained ex-
pression than plasmid DNA.
Although DNA is typically encapsulated and re-
leased from materials, cationic groups can be attached 
to the material to promote DNA binding. Collagen was 
cationized through modification with amino groups or 
polylysine43 and degradation of the collagen led to re-
lease of the bound DNA. Alternatively, PEI (polyethyl-
enimine) or polylysine was bound to or blended with 
the material,44, 45 resulting in DNA binding and some 
cellular transfection in vitro. Similarly, plasmid DNA 
adsorbed onto PLG microparticles coated with the cat-
ionic surfactant cetyltrimethylammonium bromide was 
able to transfect dendritic cells in vitro.46 Binding of plas-
mid DNA to a cationic material may exhibit limited cel-
lular internalization due to the strong interactions be-
tween the DNA and the material. The alternative is to 
allow the DNA to form complexes in solution and then 
immobilize the complexes to the polymers.
DNA Complex Delivery
Although plasmid DNA provides transfection in vivo, 
packaging DNA with cationic lipids or polymers can fa-
cilitate uptake and transfection in vitro and in vivo.27, 29, 47 
Cationic polymers and lipids protect DNA against deg-
radation by nucleases and serum components, create a 
less negative surface charge, and can be designed to tar-
get delivery to specific cell types through receptor–li-
gand interactions.47 These complexation agents can also 
facilitate intracellular trafficking, which includes endo-
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somal escape, cytoplasmic transport, and nuclear entry, 
while also dissociating from the DNA to allow expres-
sion.27, 48
Polymeric release of DNA complexes may enhance or 
localize gene transfer in vivo and in vitro; however, inter-
actions between the vector and the polymer can impact 
incorporation and release. The presence of complexation 
agents can maintain the stability of DNA complexes dur-
ing polymer processing 49, 50 and in some cases increase 
encapsulation efficiency.32 Porous PLG or collagen scaf-
folds with encapsulated polyplexes or lipoplexes achieved 
substantial transfection in vitro 6, 45, 51 and in vivo,6 but with 
significantly altered release profiles compared to plasmid 
DNA. The complexation reagents interact with the bio-
material or with adsorbed serum components, which are 
known to interact with DNA complexes.52, 53 PEI/DNA 
complexes and lipoplexes were slowly released from col-
lagen, and addition of a protective copolymer to the com-
plexes increased release, presumably by decreasing inter-
actions between collagen and the complex.6 While low 
N/P ratios supported release from synthetic polymers,50 
high N/P ratios significantly limited release.32, 51 Interest-
ingly, these vector–polymer interactions resulted in re-
leased complexes with a lower N/P ratio than the encap-
sulated complexes.54
Interactions between complexation agents and the 
polymer have been adapted to immobilize DNA com-
plexes specifically to a substrate. Poly(L-lysine) (PLL) and 
PEI were modified with biotin residues for subsequent 
complexation with DNA and binding to a neutravidin 
substrate.12, 55 Complexes were formed with mixtures of 
biotinylated and nonbiotinylated cationic polymer at a 
constant N/P ratio. Release studies demonstrated that 
only 25% of immobilized DNA complexes were released 
over an 8-day period, with approximately 15% released 
within the first 24 h. For complexes formed with PLL, the 
number of biotin groups and their distribution among the 
cationic polymers were critical determinants of both bind-
ing and transfection. The number of biotin groups in the 
complex was manipulated through the fraction of bioti-
nylated PLL used for complex formation and the number 
of biotin residues per PLL. Increasing the number of bio-
tin groups per complex led to increased binding.12 How-
ever, in vitro transfection was maximal when complexes 
contained biotin residues attached to a small fraction of 
the cationic polymers.55 At this condition, less than 100 
ng of immobilized DNA mediated transfection, which 
was increased 100-fold relative to bolus delivery of sim-
ilar complexes.12 Additionally, transfection was observed 
only in the location to which complexes were bound, sug-
gesting the possibility of spatially regulating DNA deliv-
ery. For complexes formed with PEI, substantial trans-
fection was observed in vitro but was independent of the 
number of biotin groups present on the complex, suggest-
ing that complex immobilization occurred through non-
specific interactions.55
Nonspecific binding of DNA complexes to substrates 
has been employed with other systems to mediate deliv-
ery. PLGA and collagen membranes were coated with 
phosphatidyl glycerol (1–5%) to support binding of 
complexes formed with polyamidoamine dendrimers.56 
Vectors were slowly released from this scaffold, yield-
ing transfection in vitro comparable to bolus transfection 
controls. In vivo studies demonstrated a six- to eightfold 
enhancement in transfection relative to plasmid DNA 
delivery. Adsorption of PEI/DNA complexes to silica 
nanoparticles 57, 58 resulted in transgene expression in vi-
tro comparable to that observed by bolus delivery and 
with reduced toxicity. Plasmid DNA has also been in-
corporated into inorganic calcium phosphate coprecip-
itates that are adsorbed onto PLGA matrices, which are 
mostly released by 48 h.59
Virus Delivery
Viral vectors are more widely used than nonviral vec-
tors due to their increased efficiency, yet their use re-
quires further developments to make them less toxic 
and immunogenic.60 Retroviruses and adenoviruses are 
the most widely used vectors in clinical trials, although 
other viruses are being used (herpes simplex, adeno-as-
sociated). Retroviruses offer the potential for long-term 
gene expression through integration into the host cell 
genome; however, obtaining efficient delivery, trans-
ducing nondividing cells, and achieving stable expres-
sion at an appropriate level are challenges that persist. 
Adenoviral vectors, on the other hand, can transduce a 
wide range of cells, including nondividing ones, and are 
relatively safe, though they can elicit a strong immune 
response. The stability of gene expression by adenovi-
ral vectors may also be insufficient. Viruses can be en-
gineered to be replication deficient, to reduce the im-
mune response, and to target the virus to an appropriate 
cell type. Polymeric delivery may enhance delivery effi-
ciency of viral vectors by overcoming some of the extra-
cellular barriers.
Viral particles are composed of a nucleic acid ge-
nome surrounded by a capsid of proteins, which have 
the potential to interact with a polymeric delivery sys-
tem. Most studies examining polymeric virus delivery 
have employed adenoviral vectors, which may provide 
a foundation for the use of other viral vector systems. 
Interactions with the material could provide some sta-
bility against degradation, as viruses can have half-lives 
on the order of hours at 37°C. This interaction between 
the virus and the polymer may also affect the immune 
response, which can target the vector or the transduced 
cells, thus decreasing transduction or the activity of the 
secreted protein.61–63 Polymeric delivery of viral vectors 
may reduce recognition by the immune system by limit-
ing binding of neutralizing antibodies and minimizing 
the amount of DNA necessary for gene transfer.64, 65 En-
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capsulated adenoviral vectors provided gene transfer in 
preimmunized mice,65, 66 with encapsulated vectors in-
ducing 45-fold lower anti-adenovirus titers than those 
obtained with direct injection.65, 67
Viruses can be encapsulated and released from both 
synthetic and natural materials, with the preparation 
procedure affecting both the fraction released and the 
activity. Incorporation of adenovirus into collagen re-
sulted in release of 10 to 20% depending upon the colla-
gen content.5, 68, 69 In vivo application of collagen loaded 
with viral particles resulted in localized delivery and ex-
tended availability at the site of implantation. The vi-
ral particles retained their activity in vitro and in vivo, 
with expression at implantation sites in vivo lasting for 
months without redosing.5, 64, 65, 67, 68, 70 Alternatively, 
collagen/alginate microspheres released 100% of the en-
capsulated virus within 48 h and were able to transduce 
cells in vivo at levels comparable to equivalent amounts 
of injected adenovirus.71 Microspheres composed of 
PLG released 14 to 45% of encapsulated virus in vitro, 
depending on fabrication procedures.64, 65 Virus was re-
leased for more than a week, with 70 to 90% released 
within the first 4 days 64, 65; however, most of the viable 
virus was released during the first 2 days.65
Substrate-mediated delivery of viral vectors has been 
achieved through both specific and nonspecific bind-
ing of the virus to the polymer. Polystyrene beads and 
microspheres bind adenovirus vectors nonspecifically, 
which increased transduction efficiency relative to free 
vector delivery and targeted gene expression in cells in 
contact with sphere in vitro and in vivo.72, 73 Specific in-
teractions of viral particles with the polymer have been 
incorporated through modification of the biomaterial or 
the virus with functional groups, such as antibodies or 
biotin residues. Collagen gels modified with antibodies 
to immobilize vectors localized transduction in vivo rel-
ative to control conditions.11, 74, 75 Alternatively, adeno-
virus vectors have been chemically modified with biotin 
groups that are then bound to avidin-conjugated micro-
spheres.76 This approach transduced cells immediately 
adjacent to the beads in vitro and enhanced transgene 
expression for cells that are not readily transduced with 
adenovirus.76 Recently, viruses have been engineered 
with functional groups in the viral shell, which would 
enable binding without chemical modification that can 
inactivate the virus.77–79
Applications
Polymeric delivery of nonviral and viral vectors gener-
ally promotes gene transfer to cells within or adjacent to 
the implant. Depending on the choice of gene product, 
the protein produced by transfected cells may function 
either locally or systemically. Localized protein produc-
tion is being used to stimulate an immune response, de-
liver a suicide gene, or promote wound healing. Alterna-
Table 1. In vivo studies involving therapeutically relevant genes delivered with polymeric systems.
Vector     Material          Species/location        Gene             Result                         Ref
Plasmid  Collagen  Rat/femur  BMP-4/hPTH1-34  Bone formation  [88]
Plasmid  Collagen  Canine/bone  hPTH1-34  Bone formation over 1-cm gap  [18]
Plasmid  Collagen  Mice/intramuscular  FGF-4  Platelets increased for 60 days  [17]
Plasmid  PLG  Rat/subdermal  PDGF  Enhanced matrix deposition
       and vascularization [7]
Adenovirus PVA/ Rat/subdermal  PDGF  Granulation tissue  [69]
  (FGF-2 target)   collagen
Canarypox virus  Gelatin  Mouse/intratumoral  IL-2, IL-12, TNF-a  Growth inhibition of tumors  [86]
Plasmid  Collagen  Rabbit/ear  PDGF  Granulation tissue and
       epithelialization [92]
Poly-d-lysine/ Collagen  Rat/optic nerve  FGF2, BDNF, NT-3  Survival of axotomized RGCs  [91]
   plasmid
Adenovirus  Collagen  Rabbit/ear  PDGF, FGF-2, VEGF  Granulation tissue deposition,
       wound closure, vascularization [68]
Adenovirus/ Collagen  Rat/intramuscular  PDGF, FGF-2, FGF-6  Early angiogenesis, muscle repair  [93]
   plasmid
Plasmid  PLG  Mouse/subdermal  Endothelial locus-1  Small blood vessel formation  [34]
Plasmid  Gelatin  Mouse/renal subcapsule MMP-1  Decreased blood urea nitrogen  [43]
Plasmid  Chitosan  Mouse/intranasal  RSV antigens  Reduction of viral titers and viral
        antigen load [85]
Plasmid  EVAc  Mouse/intravaginal  LDH-C4  Induction of specific IgA  [36]
Plasmid  Gelatin  Rabbit/hindlimb  FGF-4  Angiogenesis  [101]
Adenovirus  Collagen  Mouse/dermal wound  PDGF-B  Granulation tissue and
        vascularization [70]
Adenovirus  Collagen  Rabbit/dermal wound  PDGF-B  Granulation tissue, no toxicity  [70]
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tively, protein secreted by locally transfected cells can be 
distributed systemically, which has applications to dis-
orders such as hemophilia. The versatility of polymeric 
delivery to alter protein concentrations locally or sys-
temically may impact numerous applications in vivo and 
in vitro. Table 1 lists studies that have employed poly-
meric delivery in vivo to induce physiological responses.
Gene Therapy
Numerous clinical trials have been completed or are 
pending for a multitude of pathologies, including cancer 
(e.g., colorectal, bladder, and brain), monogenic disease, 
and vascular disease. Most trials have not shown signif-
icant therapeutic efficacy or clinically useful responses, 
likely due to inefficient delivery, lack of stable gene ex-
pression, and immune clearance of either the vector or 
the cells expressing a foreign gene.80–84 Polymeric-based 
gene delivery systems may enhance delivery of the vec-
tor and extend the duration of transgene expression to 
achieve sufficient protein quantities that act locally or 
systemically. For example, intranasally delivered nano-
spheres loaded with plasmid encoding RSV antigens re-
duced viral titers and viral antigen load after acute RSV 
infection in mice.85 Additionally, IL-2, IL-12, and TNF-α 
expression induced by a virus-releasing gelatin sponge 
inhibited tumor growth in heterotopic nodules of tu-
mor-bearing mice.86
Tissue Engineering
The challenge of tissue engineering lies in creating an en-
vironment that provides the appropriate combination of 
signals to induce proper cell function and restore normal 
tissue function. The scaffold functions as a support for 
cell growth and localized DNA delivery can provide the 
signals to direct progenitor cell differentiation. Although 
several fundamental requirements for the scaffold struc-
ture have been identified,87 the design principles under-
lying gene delivery in tissue regeneration remain to be 
identified. Currently, a phase I clinical study using col-
lagen-embedded adenovirus encoding PDGF has begun 
to evaluate the safety and maximum tolerated dose for 
treatment of diabetic ulcers.70 Collagen-based delivery of 
nonviral or viral DNA has been employed in models of 
bone,18, 88, 89 cartilage,90 and nerve regeneration 91; wound 
healing 68–70, 92; muscle repair 93; and cardiovascular dis-
ease.94 Alternatively, viruses have been tethered to endo-
vascular microcoils,74 stents,75 and heart valve replace-
ment cusps 95 to localize delivery to the arterial wall and 
avoid spread to distal sites.75 Porous PLG scaffolds re-
leasing plasmid DNA were able to transfect cells within 
and around the scaffold, with sufficient expression of 
PDGF to promote tissue formation.7 While these studies 
have illustrated the potential for extending the produc-
tion of growth factors locally, adapting the delivery strat-
egies to control transgene expression spatially (microme-
ters to millimeters) or temporally (days to months) may 
re-create the environmental complexity present during 
tissue formation.96 The ability to regulate expression of 
one or more factors in time and space may be critical to 
the engineering of complex tissue architectures, such as 
those found in vascular networks and the nervous sys-
tem. These systems would also increase our understand-
ing of the biology behind tissue formation, which would 
serve to identify how gene delivery can best augment the 
regenerative process.
Functional Genomics
Transfected cell arrays represent a high-throughput ap-
proach to correlate gene expression with functional cell 
responses, based on gene delivery from a surface.97 In 
principle, this system can be employed for numerous 
studies, such as screening large collections of cDNAs 
97 or targets for therapeutic intervention.98 Transfected 
cell arrays were formed using a substrate-mediated ap-
proach in which plasmids or adenoviruses were mixed 
with collagen and spotted onto glass slides or into 
wells.97–99 Plated cells were transfected and could be an-
alyzed for cellular responses using a variety of imaging 
or biochemical techniques. Further development of the 
substrate-mediated approach requires the development 
of a cost-effective delivery system that efficiently trans-
fects a wide variety of primary cells and cell lines, while 
allowing for spatially controlled DNA within the differ-
ent domains.97, 100
Conclusions
In comparison to traditional gene delivery systems, con-
trolled release can enhance gene delivery by increasing 
the extent and duration of transgene expression, while re-
ducing the need for multiple interventions. Additionally, 
localized vector delivery to specific tissues can avoid dis-
tribution to distant tissues, decrease toxicity to nontarget 
cells, and reduce the immune response. These polymer-
based gene delivery systems capitalize on both specific 
and nonspecific interactions between the biomaterial and 
the vector, to achieve either release into the extracellular 
space or immobilization at the surface. While the poten-
tial to use these polymeric systems has been established, 
the design parameters by which to optimize or control 
gene transfer are not well understood. Vector and bioma-
terial development, combined with studies that correlate 
system properties (e.g., dose, release rate) with the quan-
tity and duration of protein production and the number 
and location of cells expressing the transgene, will lead 
to molecular-scale design of delivery systems. The devel-
opment of these systems may increase the efficacy within 
current gene therapy trials and may also extend the ap-
plicability of gene delivery to other areas such as tissue 
engineering and functional genomics.
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